Virtual Library

Start Your Search

Roberto Martin



Author of

  • +

    P2.18 - Treatment of Locoregional Disease - NSCLC (ID 191)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Locoregional Disease - NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.18-19 - Radiological and Pathological Response to the Induction of Surgery in the NSCLC Stage III (Now Available) (ID 438)

      10:15 - 18:15  |  Author(s): Roberto Martin

      • Abstract
      • Slides

      Background

      Neoadjuvant treatment (NT) prior to surgical resection is the standard treatment for operable stage III-pN2 NSCLC. Our objective is to compare the response, radiological and pathological, after induction with radio-chemotherapy (RT-Ch) versus chemotherapy alone (Ch).

      Method

      We develop a retrospective study that included 53 patients from four different centres diagnosed of stage III NSCLC (TNM 8th edition). 34 patients received RT-Ch and 19 received Ch between 2012 and 2018, with a median follow-up of 25 months. The radiological response (RR) was assessed by CT at 3-4 weeks after NT using RECIST criteria. The pathologic response (PR) was evaluated in operated patients (44) through the viable residual cells in the tumor and lymph nodes. pN was taken into account to determine the rate of downstaging. The PR, as well as the surgery, were performed in the same center for all 44 patients

      Result

      The majority were stage IIIA (33), followed by IIIB (19) and only one was IV (single brain metastasis treated previously with radiosurgery). Comparing the RR in RT-Ch and Ch, we found stable disease and partial response more frequently with a 35.6% vs 52.6% and 61.8% vs 36.9% respectively. A 17.3% and 5.3% of the complete PR was achieved in RT-Ch and Ch respectively. Downstating was feasible in 82.8% of RT-Ch and 40% in Ch. Clinical features and treatment evaluation in Table 1.

      table1.jpg

      Conclusion

      In our review we observed that a 45% of the patients treated with Ch had a response of 20% or less in the pN or a local progression after the treatment, in comparison with only a 3.4% in the group of RT-Ch. However, the evaluation of the differences in the PR should be associated with a greater follow-up to assess the impact on overall survival.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.